Stock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness

Stock Track05-19 00:14

Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.

The decline follows the company's first-quarter results, which showed revenue of $15.048 million, representing a year-over-year decrease of approximately 9.6%. While the net loss per share of $0.81 beat analyst expectations and narrowed from the previous year, the revenue drop raised significant concerns about cash burn rates and the pace of pipeline advancement for this gene-editing company that has not yet commercialized any products.

Adding to the downward pressure was continued weakness in the broader biotechnology sector, with key collaboration partner Regeneron Pharmaceuticals declining 10.32% on the same day. This sector-wide negative sentiment amplified concerns about Intellia's prospects and contributed to the stock's significant intraday decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175852830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175852830","market":"nz","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness","media":"Stock Track","content":"<p>Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.</p><p>The decline follows the company's first-quarter results, which showed revenue of $15.048 million, representing a year-over-year decrease of approximately 9.6%. While the net loss per share of $0.81 beat analyst expectations and narrowed from the previous year, the revenue drop raised significant concerns about cash burn rates and the pace of pipeline advancement for this gene-editing company that has not yet commercialized any products.</p><p>Adding to the downward pressure was continued weakness in the broader biotechnology sector, with key collaboration partner Regeneron Pharmaceuticals declining 10.32% on the same day. This sector-wide negative sentiment amplified concerns about Intellia's prospects and contributed to the stock's significant intraday decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.</p><p>The decline follows the company's first-quarter results, which showed revenue of $15.048 million, representing a year-over-year decrease of approximately 9.6%. While the net loss per share of $0.81 beat analyst expectations and narrowed from the previous year, the revenue drop raised significant concerns about cash burn rates and the pace of pipeline advancement for this gene-editing company that has not yet commercialized any products.</p><p>Adding to the downward pressure was continued weakness in the broader biotechnology sector, with key collaboration partner Regeneron Pharmaceuticals declining 10.32% on the same day. This sector-wide negative sentiment amplified concerns about Intellia's prospects and contributed to the stock's significant intraday decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1175852830","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175852830","pubTimestamp":1779120846,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.The decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|Intellia Therapeutics盘中暴跌8.12%受Q1营收下滑及生物科技板块疲软影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.The decline follows the company's first-quarter results, which showed revenue of $15.048 million, representing a year-over-year decrease of approximately 9.6%. While the net loss per share of $0.81 beat analyst expectations and narrowed from the previous year, the revenue drop raised significant concerns about cash burn rates and the pace of pipeline advancement for this gene-editing company that has not yet commercialized any products.Adding to the downward pressure was continued weakness in the broader biotechnology sector, with key collaboration partner Regeneron Pharmaceuticals declining 10.32% on the same day. This sector-wide negative sentiment amplified concerns about Intellia's prospects and contributed to the stock's significant intraday decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175852830","isCrawlerRequest":true}